LYVE-1 Antibody [DyLight 488]

Immunohistochemistry-Paraffin: LYVE1 Antibody [DyLight 488] [NB100-725G] - IHC analysis of LYVE1 in paraffin embedded MDA-MB-231 breast cancer orthotopic transplantation tissue. Image courtesy of product review submitted by Luana Schito.

Flow Cytometry: LYVE-1 Antibody [DyLight 488] [NB100-725G] - An intracellular stain was performed on A549 cells with LYVE-1 Antibody NB100-725G (blue) and a matched isotype control (orange). Cells were fixed with 4% PFA and then permeabilized with 0.1% saponin. Cells were incubated in an antibody dilution of 10 ug/mL for 30 minutes at room temperature. Both antibodies were conjugated to Dylight 488

Flow Cytometry: LYVE1 Antibody [DyLight 488] [NB100-725G] - Unlabeled control with labeled samples of cells dissociated mechanically and enzymatically from human skin. Image provided via product review by Patricia Redondo.

• Reactivity: Hu, Mu, Rt
• Applications: WB, Flow, IHC
• Clonality: Polyclonal
• Host: Rabbit
• Conjugate: DyLight 488

LYVE-1 Antibody [DyLight 488] Summary

• Immunogen: This LYVE-1 Antibody was developed against a synthetic peptide made to a C-terminal portion of the mouse LYVE1 protein sequence (between residues 250-318). [UniProt# Q8BHC0]
• Localization: Plasma membrane
• Marker: Lymphatic Vessel Marker
• Isotype: IgG
• Clonality: Polyclonal
• Host: Rabbit
• Gene: LYVE1
• Purity: Immunogen affinity purified

Applications/Dilutions

• Dilutions:
  • Flow (Intracellular)
  • Flow Cytometry
  • Immunohistochemistry
  • Immunohistochemistry-Frozen
  • Immunohistochemistry-Paraffin
  • Western Blot
• Application Notes: Optimal dilution of this antibody should be experimentally determined.
• Theoretical MW: 35 kDa.
  Disclaimer note: The observed molecular weight of the protein may vary from the listed predicted molecular weight due to post translational modifications, post translation cleavages, relative charges, and other experimental factors.

Packaging, Storage & Formulations

• Storage: Store at 4C in the dark.
• Buffer: 50mM Sodium Borate
• Preservative: 0.05% Sodium Azide
• Purity: Immunogen affinity purified

Notes

DyLight (R) is a trademark of Thermo Fisher Scientific Inc. and its subsidiaries.

Alternate Names for LYVE-1 Antibody [DyLight 488]

• cell surface retention sequence binding protein-1
• Cell surface retention sequence-binding protein 1
• CRSBP1
• CRSBP-1
• extracellular link domain containing 1
• extracellular link domain-containing 1
• Extracellular link domain-containing protein 1
• HAR
• Hyaluronic acid receptor
• lymphatic vessel endothelial hyaluronan receptor 1
• lymphatic vessel endothelial hyaluronic acid receptor 1
• LYVE1
• LYVE-1
• UNQ230/PRO263
• XLKD1

Background

LYVE-1 (Lymphatic Vessel Endothelial Receptor 1) is a receptor for the extracellular matrix mucopolysaccharide hyaluronan (HA) and is primarily expressed by lymphatic endothelial cells in addition to the sinusoidal endothelium of the liver and spleen (1-3). HA, also called hyaluronic acid, is a main component of the extracellular matrix and functions largely in cell adhesion, migration, and tissue remodeling (2). HA undergoes a turnover process that involves release from the tissues to the afferent lymph, degradation within the lymph nodes, and removal of fragments by the liver (2,3). LYVE-1, in addition to other lymphatic proteins including VEGFR3, Prox1, and podoplanin, is a common marker for differentiating between the blood and lymphatic systems (2,3). Furthermore, LYVE-1 is closely related to the leukocyte receptor CD44, having ~44% sequence similarity (1-3). Like CD44, the LYVE-1 protein contains an extracellular HA-binding link domain, with N- and C-terminal extensions, located at the end of a glycosylated juxtamembrane domain stalk region, followed by a transmembrane region, and a cytoplasmic tail (1-3). The key features of the HA-binding like molecule are the three disulfide bridges formed by six cysteine residues (1-3). LYVE-1 is synthesized as a protein of 322 amino acids in length with a theoretical molecular weight of 35 kDa, although due to O-glycosylation often appears in SDS-PAGE at a molecular weight ranging from ~60-70 kDa (2,4). The role of HA-binding is further elucidated by the identification of LYVE-1 as a docking receptor for dendritic cells and macrophages, binding their surface HA to control the entry and migration into lymph vessels (1).

LYVE-1 has been an important marker in studies of embryonic and tumor lymphangiogenesis, as many cancers are characterized by early metastasis to the lymph nodes (1-3, 5). One study of five different vascular tumors in infants used immunohistochemical analysis and found positive LYVE-1 expression in infantile hemangioma, tufted angioma, and kaposiform hemangioendothelioma (5). LYVE-1 along with other markers such as GLUT-1, CD31, CD34, Prox-1, and WT-1 can be used to help provide immunohistologic profiles of various tumors and, when used in conjunction with clinical and histopathologic approaches, may offer better overall diagnosis and disease treatment (5).

References

1. Jackson D. G. (2019). Hyaluronan in the lymphatics: The key role of the hyaluronan receptor LYVE-1 in leucocyte trafficking. Matrix Biology : Journal of the International Society for Matrix Biology. https://doi.org/10.1016/j.matbio.2018.02.001

2. Jackson D. G. (2004). Biology of the lymphatic marker LYVE-1 and applications in research into lymphatic trafficking and lymphangiogenesis. APMIS : acta pathologica, microbiologica, et immunologica Scandinavica. https://doi.org/10.1111/j.1600-0463.2004.apm11207-0811.x

3. Jackson D. G. (2003). The lymphatics revisited: new perspectives from the hyaluronan receptor LYVE-1. Trends in Cardiovascular Medicine. https://doi.org/10.1016/s1050-1738(02)00189-5

4. Unitprot (Q9Y5Y7)

5. Johnson, E. F., Davis, D. M., Tollefson, M. M., Fritchie, K., & Gibson, L. E. (2018). Vascular Tumors in Infants: Case Report and Review of Clinical, Histopathologic, and Immunohistochemical Characteristics of Infantile Hemangioma, Pyogenic Granuloma, Noninvoluting Congenital Hemangioma, Tufted Angioma, and Kaposiform Hemangioendothelioma. The American Journal of Dermatopathology. https://doi.org/10.1097/DAD.0000000000000983

Limitations

This product is for research use only and is not approved for use in humans or in clinical diagnosis. Primary Antibodies are guaranteed for 1 year from date of receipt.

Reviews for LYVE-1 Antibody (NB100-725G) (2)

Average Rating: 5

(Based on 2 reviews)

We have 2 reviews tested in 1 species: Human.

reviewed by: Verified Customer Flow Human 06/18/2013

Summary

• Application: Flow Cytometry
• Sample Tested: Stromal vascular fraction from skin
• Species: Human

reviewed by: Verified Customer IHC-P Human 11/16/2010

Summary

• Application: Immunohistochemistry-Paraffin
• Sample Tested: MDA-MB-231 breast cancer orthotopic transplantation
• Species: Human
• Lot: A-A

Bioinformatics

• Gene Symbol: LYVE1